Aug 2026· Journal of the American Society for Mass Spectrometry· Vol 37 9, pp.
2215-2227
· 0 citations· 43 references
Medicine
TL;DR
Covalent labeling experiments in a cellular environment with the same model system and with results consistent with purified proteins are extended, making covalent labeling a suitable method to screen epitopes for complex targets and receptors directly from cells.
Abstract
Validation of epitopes and paratopes for antibodies and antigens is crucial for understanding antibody binding and is of interest in the pharmaceutical field. Traditionally, high-resolution techniques like X-ray and NMR are used for delineating protein-protein interactions, but they are prone to sample preparation problems and size limitations. Mass spectrometry (MS)-based structural analysis, like H/D exchange (HDX), covalent labeling, and cross-linking, contributes unique information and advantages relative to traditional methods. As such, it is desirable to compare all three techniques side by side and assess how complementary their results are for defining epitopes on the targets of interest. In this study, we probed interaction sites of epidermal growth factor receptor (EGFR) with cetuximab and zalutumumab using HDX, covalent labeling, and cross-linking techniques. For covalent labeling experiments, sulfo-NHS acetate and DEPC were used as the labeling reagents. In cross-linking experiments, multiple cross-linkers, including BS3, EDC, DSSO, and ADH/DMTMM, were used for a comprehensive search of protein-protein interactions. The results from cross-linking and covalent labeling were compared to HDX as well as known epitopes. Covalent labeling, cross-linking, and HDX data showed consistent results for EGFR-Cetuximab epitopes. For the EGFR-Zalutumumab complex, no intermolecular cross-links within reasonable distances were identified, but the epitopes observed from covalent labeling agree with HDX. The results are consistent with reported crystal structures. Overall results with DEPC and sulfo-NHS labeling are comparable to HDX with a faster cycle time, making them amenable for rapid screening of many molecules. DEPC labeling has more residue coverage compared to sulfo-NHS acetate but faces unique challenges like faster hydrolysis and more complex modifications. We further extended the use of covalent labeling experiments in a cellular environment with the same model system and with results consistent with purified proteins, making covalent labeling a suitable method to screen epitopes for complex targets and receptors directly from cells.
It is demonstrated that FR-targeted XL-MS provides a strategy for identifying epitopes within patient-derived IC-antigens through the use of conserved antibody FRs and may contribute to understanding antigen recognition mechanisms in autoimmune diseases and support the discovery of disease-relevant therapeutic targets.
Nozomi Aibara, R. Yamazawa, Yuya Matsugi et al.· Journal of Pharmaceutical an...· 0 citations
ABSTRACT Recombinant biomacromolecules have significantly transformed pharmaceuticals, in particular monoclonal antibodies (mAbs) that target key areas in oncology, immunology, inflammation, and neurodegenerative diseases. Developing biotherapeutics requires a detailed understanding of their biological properties. This...
Francesca Sacco, F. Baroni, A. Capolupo et al.· Angewandte Chemie· 0 citations
Antibody–drug conjugates (ADCs) are biotherapeutics that are structurally heterogeneous due to the way each ADC is formed. Therefore, complementary analytical approaches need to be used in order to achieve a complete characterization of all aspects of the structure of these biotherapeutics. This project created a multi...
HeeJae Yoo, Abhik Mojumdar, Minsun Kim et al.· Journal of Analytical Scienc...· 0 citations
A hydrogen-deuterium exchange mass spectrometry (HDX-MS)-guided structural modeling workflow for efficient and accurate epitope and paratope mapping across three prospective case studies in therapeutic protein discovery and engineering is presented.
William P. McMahon, Han-Zhi Zhang, Xiu-Ling Li et al.· mAbs· 0 citations
The molecular mechanism underlying the effector function of therapeutic antibodies and the advanced quality assessment methods developed in this study are expected to contribute to the promotion of development and quality assurance of next-generation therapeutic antibodies that continue to evolve through diverse molecu...
Masato Kiyoshi· Yakugaku Zasshi-journal of T...· 0 citations
Anti-idiotype antibodies are essential tools for therapeutic drug monitoring of biologic therapies in cancer, inflammatory bowel disease, and rheumatoid arthritis. While several platforms exist for their development, including B-cell immortalization and phage display, we employ a proteomics-based mass spectrometr...
J. Crha, T. Le Bihan, T. N. de Villavicencio Diaz et al.· Clinical Chemistry· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.